Binnopharm may become leading player in Russian OTC drugs market

Russian drugmaker Binnopharm, which is owned by the local financial conglomerate AFK Systema, may become a leading player in the Russian market of over-the-counter (OTC) drugs in the coming years, reports The Pharma Letter’s local correspondent.

This is the expected result of Binnopharma’s acquisition of its local competitor Alpharm, a company whose portfolio of drugs includes an antiviral Kipferon drug, as well as Prostopin, a drug which is used in the treatment of hemorrhoids and prostatitis.

Kipferon currently remains the fourth largest interferon-based immunomodulator in terms of sales in the market segment, the value of which is estimated at about 3 billion roubles (~$47 million).